[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"PARAGON VISION SCIENCES, Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":74},{"warningLetters":4,"total":73},[5,30,49],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":27,"delivery_method":28,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},241,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-04-07T04:00:00Z\">04\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026\">Prime Sciences\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs Sold Over the Internet","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Prime Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14500 N. Northsight Blvd, STE 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@prime-sciences.com\"> info@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@prime-sciences.com\"> support@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 31, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 721805\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prime Sciences:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Cagrilintide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\u003C\u002Fp>\u003Cul>\u003Cli>“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\u003C\u002Fli>\u003Cli>“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-R (10MG) (identified as Retatrutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\u003C\u002Fp>\u003Cul>\u003Cli>“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\u003C\u002Fli>\u003Cli>“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-S (10MG) (identified as Semaglutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\u003C\u002Fp>\u003Cul>\u003Cli>“Ozempic – Weight Loss Supplement.”\u003C\u002Fli>\u003Cli>“Semaglutide peptide therapy benefits include:\u003Cbr>o Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\u003Cbr>o Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\u003Cbr>o Reduces blood sugar levels to promote weight loss”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-T (10MG) (identified as Tirzepatide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\u003C\u002Fp>\u003Cul>\u003Cli>“Tirzepatide therapy benefits include:\u003Cbr>o A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\u003Cbr>o Stimulates the production of insulin to lower blood sugar\u003Cbr>o Reduces appetite by slowing the time it takes the stomach to empty”\u003C\u002Fli>\u003Cli>“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>MAZDUTIDE (10MG)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\u003C\u002Fp>\u003Cul>\u003Cli>“Mazdutide peptide therapy benefits include:\u003Cbr>o Weight Management\u003Cbr>􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\u003C\u002Fli>\u003Cli>“Improved metabolic health\u003Cbr>o Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\u003Cbr>o Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\u003Cbr>o Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>BAC water\u003C\u002Fu>\u003Cbr>Your firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\u003C\u002Fp>\u003Cp>Your Prime Sciences products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPrime Sciences\n\n14500 N. Northsight Blvd, STE 100\n\nScottsdale, AZ 85260\n\nUnited States\n\ninfo@prime-sciences.com\n\nsupport@prime-sciences.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 31, 2026\nRE: 721805\nPrime Sciences:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThese products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\nDespite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\nExamples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nCagrilintide\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\n“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\n“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-R (10MG) (identified as Retatrutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\n“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\n“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\nGLP1-S (10MG) (identified as Semaglutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\n“Ozempic – Weight Loss Supplement.”\n“Semaglutide peptide therapy benefits include:\no Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\no Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\no Reduces blood sugar levels to promote weight loss”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-T (10MG) (identified as Tirzepatide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\n“Tirzepatide therapy benefits include:\no A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\no Stimulates the production of insulin to lower blood sugar\no Reduces appetite by slowing the time it takes the stomach to empty”\n“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\nMAZDUTIDE (10MG)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\n“Mazdutide peptide therapy benefits include:\no Weight Management\n􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\n“Improved metabolic health\no Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\no Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\no Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\nBAC water\nYour firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\nYour Prime Sciences products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Prime Sciences","prime-sciences-721805-03312026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026","2026-10-26T08:09:44.094362+00:00","Warning Letter","Issued","2026-04-07","721805","Drugs","2026-08-19T04:49:30.204+00:00","Via Email","2026-03-31",{"id":31,"raw":32,"subject":36,"body_html":37,"body_text":38,"firm_name":39,"letter_id":40,"created_at":18,"fei_number":19,"letter_url":41,"updated_at":42,"action_type":22,"case_status":23,"posted_date":43,"marcs_cms_no":44,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":45,"body_fetched_at":46,"delivery_method":47,"recipient_title":19,"reference_number":19,"action_taken_date":48,"medical_device_id":19,"response_letter_date":19},473,[33,34,35,11,36,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-10T05:00:00Z\">11\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fverdure-sciences-inc-717259-11102025\">Verdure Sciences, Inc.\u003C\u002Fa>","Sponsor\u002FInvestigator","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ajay S. Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Verdure Sciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>17150 Metro Park Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Noblesville\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46060-4051\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 25-HFD-45-11-01\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between June 25 and July 12, 2024. The investigators representing FDA reviewed the role of Verdure Sciences, Inc. (Verdure) as the sponsor of a clinical investigation (Protocol 005, “Randomized, Double-Blind Evaluation of Maple leaf extract (Maplifa for Photoaging”) of the investigational drug Maplifa® (1% or 5%).\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 24, 2024, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 24, 2024, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312), governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20(a) and (b) and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2. Verdure failed to comply with these requirements. Specifically, Verdure initiated Protocol 005, a clinical investigation of the investigational drug Maplifa®, which is subject to section 505 of the FD&amp;C Act [21 U.S.C. 355], without submitting and having in effect an IND.\u003C\u002Fp>\u003Cp>In Verdure’s July 24, 2024, written response to the Form FDA 483, you stated that Verdure did not believe an IND was required because Protocol 005 assessed the use of topical Maplifa® skin regimen on the cosmetic appearance of skin photoaging (wrinkles and skin brightness). You further stated that the study ingredient was not being studied for use to affect the structure or function of the body or to prevent, treat, mitigate, cure, or diagnose a disease because Protocol 005’s primary endpoint was to detect change in skin brightness as measured by a skin colorimeter and facial photographic image analysis, which are widely used to study the efficacy of cosmetic formulations. Furthermore, you stated that the study met all the IND exemption requirements as listed in an FDA proposed rule\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> that proposed exemptions for certain clinical investigations of products lawfully marketed as a food or cosmetic when the product is to be studied to evaluate its use as a drug. Finally, you stated that Verdure signed a Clinical Study Agreement (CSA) with a third-party vendor to conduct Protocol 005, and the CSA transferred the obligation of the “sponsor” to this third party.\u003C\u002Fp>\u003Cp>We address your arguments below.\u003C\u002Fp>\u003Cp>1. Protocol 005 was a clinical investigation of a drug subject to 21 CFR 312.\u003C\u002Fp>\u003Cp>Section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)] defines \u003Cem>drug\u003C\u002Fem>, in part, as “articles (other than food) intended to affect the structure or any function of the body of man or other animals….” Whether an investigational article is a drug depends on the intended use of the article in the investigation. Based on Protocol 005 and the final study report, the investiga-tional product, Maplifa®, as used in this clinical investigation, was a drug as defined in section 201(g)(1) of the FD&amp;C Act because Maplifa® was studied for use in the mitigation or treatment of facial wrinkles, skin brightness, skin redness, erythema, and hyperpigmentation.\u003C\u002Fp>\u003Cp>Specifically, as described in the protocol, the objective of Protocol 005 was to “examine the effects of topical Maplifa® on facial wrinkles, redness, and pigmentation.” The final study report for Protocol 005 also stated that “Maplifa® is a proprietary, standardized, phenolic-enriched A[cer] \u003Cem>rubrum\u003C\u002Fem> extract formula that is intended to whiten skin and reduce wrinkle production, primarily due to its anti-oxidative and anti-glycating properties.” The final study report further stated, “To further understand the influence of applying topical \u003Cem>A. rubrum\u003C\u002Fem>-based products to the skin, we conducted a randomized, double-blind evaluation to explore the influence of [glucitol-core containing gallotannins] on reduction of face redness, hyperpigmen-tation, and wrinkle formation.” According to the protocol and the final study report, to assess the efficacy of Maplifa®, Protocol 005’s outcome measures included changes in skin brightness, pigmentation, erythema, redness, and wrinkles. These outcomes were measured using different methods, including skin colorimeter, image-based analysis, and in-person clinical assessments. Therefore, Protocol 005 collected study data to assess the effect of Maplifa® on the skin, as measured by methods including skin colorimeter and facial photographic image analysis.\u003C\u002Fp>\u003Cp>Considering the nature of the study, as described above, we conclude that the evidence collected during the inspection shows that Maplifa® was intended to affect the structure or function of the body; it was not merely intended to affect cosmetic appearance. Maplifa® was therefore intended for use as a drug for the clinical investigation conducted under Protocol 005. As a result, you were required to submit an IND before conducting the clinical investigation.\u003C\u002Fp>\u003Cp>\u003Cem>2. The clinical investigation conducted under Protocol 005 does not meet the exemption criteria in 21 CFR 312.2(b)(1) and is subject to the IND requirements under 21 CFR 312.\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA regulations require a sponsor to submit an IND before conducting a clinical investigation of a drug in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2(b). Under 21 CFR 312.2(b)(1), the clinical investigation of a lawfully marketed drug product in the United States is exempt from the IND regulations for a clinical investigation if all the exemption criteria in 21 CFR 312.2(b) are met.\u003C\u002Fp>\u003Cp>Protocol 005 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must be lawfully marketed in the United States as a drug product. Verdure’s July 24, 2024, written response claims that Maplifa® is marketed only as a cosmetic ingredient, not as a drug product. However, as described above, the intended use of Maplifa® under Protocol 005 was as a drug, and we are not aware of any basis to conclude that it is a lawfully marketed drug. You also argue that Maplifa® is exempt from the IND requirements based on an FDA proposed rule. However, your response provided no reasoning to support this assertion. A proposed rule, until final, is not binding and does not supersede or otherwise change existing FDA regulations regarding IND exemptions. Your response also did not explain why Protocol 005 would have qualified for an exemption, even if the proposed rule were final and in effect. Moreover, we note that study participants received the study drug and the study was completed before FDA proposed the regulation at issue for public comment. As explained above, the study materials for Protocol 005 establish that Maplifa®’s intended use in the clinical trial was that of a drug. Further, Protocol 005 was not exempt from 21 CFR 312, and Verdure was required to submit an IND before initiating a clinical investigation of a drug in human subjects.\u003C\u002Fp>\u003Cp>\u003Cem>3. Verdure is the sponsor of the clinical investigation conducted under Protocol 005 as defined in 21 CFR 312.3.\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA regulations define a sponsor as a person who takes responsibility for and initiates a clinical investigation [see 21 CFR 312.3]. Under 21 CFR 312.52, a sponsor may transfer responsibility for any or all of its obligations to a Contract Research Organization (CRO) and must describe any such transfer, including the specific obligations transferred, in writing; however, if all obligations are transferred, a general statement that all obligations have been transferred is acceptable. Both the CSA and the work order collected during the inspection and provided in your written response identify Verdure Sciences, Inc., as the “Sponsor” and the third-party vendor as the “Service Provider.” Neither of these documents describes which of Verdure’s sponsor obligations for conducting this study, if any, were transferred to the third-party vendor. Additionally, the CSA and work order do not contain any general statements that sponsor obligations have been transferred. Your written response refers to a provision of the CSA, which states that the third-party vendor “will conduct the Study according to the provisions of the Protocol and this Agreement and in conformance with all [Applicable Laws].” This provision does not describe, in either general or specific terms, any obligations that transferred from you to the third-party vendor.\u003C\u002Fp>\u003Cp>In your written response, you stated that as a corrective and preventive action, Verdure will ensure that all third parties, such as a CRO, comply with all applicable FDA regulations, including filing for an IND, unless exempt. However, your written response is inadequate because it does not provide sufficient details of a corrective and preventive action plan for developing and implementing procedures that comply with IND regulations, should Verdure decide in the future to initiate another clinical investigation for which an IND is required. Without this information, we are unable to determine whether Verdure will comply with IND regulations in the future.\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible for complying with IND requirements, including submitting and having in effect an IND before initiating a clinical investigation, and it is Verdure’s responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. Verdure’s failure to submit, and to have in effect, an IND before initiating Protocol 005 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of the data collected during the conduct of this clinical investigation.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Should you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\u003Cp>Brittany L. Garr, MPH\u003Cbr>Branch Chief\u003Cbr>Compliance Enforcement Branch\u003Cbr>Division of Enforcement and Postmarketing Safety\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>Building 51, Room 5352\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Federal Register Proposed Rule - December 9, 2022.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAjay S. Patel\n\nRecipient Title\n\nCEO\n\nVerdure Sciences, Inc.\n\n17150 Metro Park Court\n\nNoblesville, IN 46060-4051\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 25-HFD-45-11-01\n\nDear Mr. Patel:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between June 25 and July 12, 2024. The investigators representing FDA reviewed the role of Verdure Sciences, Inc. (Verdure) as the sponsor of a clinical investigation (Protocol 005, “Randomized, Double-Blind Evaluation of Maple leaf extract (Maplifa for Photoaging”) of the investigational drug Maplifa® (1% or 5%).\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\nAt the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 24, 2024, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 24, 2024, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312), governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\nYou failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\nFDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20(a) and (b) and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2. Verdure failed to comply with these requirements. Specifically, Verdure initiated Protocol 005, a clinical investigation of the investigational drug Maplifa®, which is subject to section 505 of the FD&C Act [21 U.S.C. 355], without submitting and having in effect an IND.\nIn Verdure’s July 24, 2024, written response to the Form FDA 483, you stated that Verdure did not believe an IND was required because Protocol 005 assessed the use of topical Maplifa® skin regimen on the cosmetic appearance of skin photoaging (wrinkles and skin brightness). You further stated that the study ingredient was not being studied for use to affect the structure or function of the body or to prevent, treat, mitigate, cure, or diagnose a disease because Protocol 005’s primary endpoint was to detect change in skin brightness as measured by a skin colorimeter and facial photographic image analysis, which are widely used to study the efficacy of cosmetic formulations. Furthermore, you stated that the study met all the IND exemption requirements as listed in an FDA proposed rule1 that proposed exemptions for certain clinical investigations of products lawfully marketed as a food or cosmetic when the product is to be studied to evaluate its use as a drug. Finally, you stated that Verdure signed a Clinical Study Agreement (CSA) with a third-party vendor to conduct Protocol 005, and the CSA transferred the obligation of the “sponsor” to this third party.\nWe address your arguments below.\n1. Protocol 005 was a clinical investigation of a drug subject to 21 CFR 312.\nSection 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)] defines drug, in part, as “articles (other than food) intended to affect the structure or any function of the body of man or other animals….” Whether an investigational article is a drug depends on the intended use of the article in the investigation. Based on Protocol 005 and the final study report, the investiga-tional product, Maplifa®, as used in this clinical investigation, was a drug as defined in section 201(g)(1) of the FD&C Act because Maplifa® was studied for use in the mitigation or treatment of facial wrinkles, skin brightness, skin redness, erythema, and hyperpigmentation.\nSpecifically, as described in the protocol, the objective of Protocol 005 was to “examine the effects of topical Maplifa® on facial wrinkles, redness, and pigmentation.” The final study report for Protocol 005 also stated that “Maplifa® is a proprietary, standardized, phenolic-enriched A[cer] rubrum extract formula that is intended to whiten skin and reduce wrinkle production, primarily due to its anti-oxidative and anti-glycating properties.” The final study report further stated, “To further understand the influence of applying topical A. rubrum-based products to the skin, we conducted a randomized, double-blind evaluation to explore the influence of [glucitol-core containing gallotannins] on reduction of face redness, hyperpigmen-tation, and wrinkle formation.” According to the protocol and the final study report, to assess the efficacy of Maplifa®, Protocol 005’s outcome measures included changes in skin brightness, pigmentation, erythema, redness, and wrinkles. These outcomes were measured using different methods, including skin colorimeter, image-based analysis, and in-person clinical assessments. Therefore, Protocol 005 collected study data to assess the effect of Maplifa® on the skin, as measured by methods including skin colorimeter and facial photographic image analysis.\nConsidering the nature of the study, as described above, we conclude that the evidence collected during the inspection shows that Maplifa® was intended to affect the structure or function of the body; it was not merely intended to affect cosmetic appearance. Maplifa® was therefore intended for use as a drug for the clinical investigation conducted under Protocol 005. As a result, you were required to submit an IND before conducting the clinical investigation.\n2. The clinical investigation conducted under Protocol 005 does not meet the exemption criteria in 21 CFR 312.2(b)(1) and is subject to the IND requirements under 21 CFR 312.\nFDA regulations require a sponsor to submit an IND before conducting a clinical investigation of a drug in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2(b). Under 21 CFR 312.2(b)(1), the clinical investigation of a lawfully marketed drug product in the United States is exempt from the IND regulations for a clinical investigation if all the exemption criteria in 21 CFR 312.2(b) are met.\nProtocol 005 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must be lawfully marketed in the United States as a drug product. Verdure’s July 24, 2024, written response claims that Maplifa® is marketed only as a cosmetic ingredient, not as a drug product. However, as described above, the intended use of Maplifa® under Protocol 005 was as a drug, and we are not aware of any basis to conclude that it is a lawfully marketed drug. You also argue that Maplifa® is exempt from the IND requirements based on an FDA proposed rule. However, your response provided no reasoning to support this assertion. A proposed rule, until final, is not binding and does not supersede or otherwise change existing FDA regulations regarding IND exemptions. Your response also did not explain why Protocol 005 would have qualified for an exemption, even if the proposed rule were final and in effect. Moreover, we note that study participants received the study drug and the study was completed before FDA proposed the regulation at issue for public comment. As explained above, the study materials for Protocol 005 establish that Maplifa®’s intended use in the clinical trial was that of a drug. Further, Protocol 005 was not exempt from 21 CFR 312, and Verdure was required to submit an IND before initiating a clinical investigation of a drug in human subjects.\n3. Verdure is the sponsor of the clinical investigation conducted under Protocol 005 as defined in 21 CFR 312.3.\nFDA regulations define a sponsor as a person who takes responsibility for and initiates a clinical investigation [see 21 CFR 312.3]. Under 21 CFR 312.52, a sponsor may transfer responsibility for any or all of its obligations to a Contract Research Organization (CRO) and must describe any such transfer, including the specific obligations transferred, in writing; however, if all obligations are transferred, a general statement that all obligations have been transferred is acceptable. Both the CSA and the work order collected during the inspection and provided in your written response identify Verdure Sciences, Inc., as the “Sponsor” and the third-party vendor as the “Service Provider.” Neither of these documents describes which of Verdure’s sponsor obligations for conducting this study, if any, were transferred to the third-party vendor. Additionally, the CSA and work order do not contain any general statements that sponsor obligations have been transferred. Your written response refers to a provision of the CSA, which states that the third-party vendor “will conduct the Study according to the provisions of the Protocol and this Agreement and in conformance with all [Applicable Laws].” This provision does not describe, in either general or specific terms, any obligations that transferred from you to the third-party vendor.\nIn your written response, you stated that as a corrective and preventive action, Verdure will ensure that all third parties, such as a CRO, comply with all applicable FDA regulations, including filing for an IND, unless exempt. However, your written response is inadequate because it does not provide sufficient details of a corrective and preventive action plan for developing and implementing procedures that comply with IND regulations, should Verdure decide in the future to initiate another clinical investigation for which an IND is required. Without this information, we are unable to determine whether Verdure will comply with IND regulations in the future.\nAs a sponsor, you are responsible for complying with IND requirements, including submitting and having in effect an IND before initiating a clinical investigation, and it is Verdure’s responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. Verdure’s failure to submit, and to have in effect, an IND before initiating Protocol 005 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of the data collected during the conduct of this clinical investigation.\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nShould you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\nBrittany L. Garr, MPH\nBranch Chief\nCompliance Enforcement Branch\nDivision of Enforcement and Postmarketing Safety\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nBuilding 51, Room 5352\n10903 New Hampshire Avenue\nSilver Spring, MD 20993\nSincerely yours,\n\u002FS\u002F\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________\n1 Federal Register Proposed Rule - December 9, 2022.","Verdure Sciences, Inc.","verdure-sciences-inc-717259-11102025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fverdure-sciences-inc-717259-11102025","2026-10-26T08:10:27.247507+00:00","2025-11-18","717259","Ajay S. Patel","2026-08-19T14:55:40.536+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2025-11-10",{"id":50,"raw":51,"subject":57,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":62,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":55,"recipient_name":68,"body_fetched_at":69,"delivery_method":70,"recipient_title":19,"reference_number":71,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},2429,[52,53,54,55,56,13,13,13],"\u003Ctime datetime=\"2022-09-20T13:20:00Z\">09\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-23T04:00:00Z\">08\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022\">BioLab Sciences, Inc.\u003C\u002Fa>","Office of Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 621465\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert D. Maguire\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioLab Sciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13825 N. Northsight Blvd., Suite 101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 23, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Maguire:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1,2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\u003C\u002Fp>\n\n\u003Cp>Based on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\u003C\u002Fp>\n\n\u003Cp>MyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\u003C\u002Fp>\n\n\u003Cp>Because Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>In order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\u003C\u002Fp>\n\n\u003Cp>Your CGMP deficiencies, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You failed to validate the aseptic processes used to manufacture over&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> units of Fluid Flow™, Amnio Restore™,\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of these products since June 22, 2021.\u003C\u002Fp>\n\n\u003Cp>c. Your Fluid Flow™ \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation, entitled “\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You did not assess the impact of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\u003C\u002Fp>\n\n\u003Cp>d. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. Personnel monitoring is required only every \u003Cstrong>(b)(4)\u003C\u002Fstrong> for personnel who process your amniotic fluid products.\u003C\u002Fp>\n\n\u003Cp>e. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\u003C\u002Fp>\n\n\u003Cp>f. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\u003C\u002Fp>\n\n\u003Cp>g. Your written environmental monitoring procedure now describes that \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca>www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your BSCs.\u003Cbr>\n\u003Cbr>\nb. Your firm has not adequately established and followed written procedures for cleaning the \u003Cstrong>(b)(4)\u003C\u002Fstrong> BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the \u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used to clean the BSCs during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your cleanrooms.\u003C\u002Fp>\n\n\u003Cp>b. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. In accordance with your cleanroom cleaning procedure, a \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>cleaning of all contact surfaces in the cleanrooms is required at the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> processing operations. However, a review of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. You failed to ensure sufficient use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified \u003Cem>Bacillus\u003C\u002Fem>, species, a spore-forming organism, on your cleanroom floors. You noted that \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iii. Your written procedure for cleanroom cleaning does not include the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanings.\u003C\u002Fp>\n\n\u003Cp>&nbsp; iv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)].\u003C\u002Fstrong> For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its&nbsp;\u003C\u002Fstrong>\u003Cstrong>specifications whether or not the batch has been already distributed [21 CFR 211.192].\u003C\u002Fstrong> For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include \u003Cem>Bacillus\u003C\u002Fem> species non-anthracis, \u003Cem>Fictibacillus\u003C\u002Fem> species, \u003Cem>Bacillus pumilus\u003C\u002Fem>, Gram Positive Cocci, fungi, and \u003Cem>Bacillus megaterium\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\u003C\u002Fp>\n\n\u003Cp>b. Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\u003C\u002Fp>\n\n\u003Cp>c. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, Fluid Flow™, and Amnio Restore™.\u003C\u002Fp>\n\n\u003Cp>Your responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\u003C\u002Fp>\n\n\u003Cp>We note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\u003C\u002Fp>\n\n\u003Cp>Finally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>Cc: Robert D. Maguire\u003Cbr>\nPresident and Chief Executive Officer\u003Cbr>\nBioLab Sciences, Inc.\u003Cbr>\n7662 East Gray Road, Suite 107\u003Cbr>\nScottsdale, AZ 85260\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Some of your products are the same products marketed under different brand names. For example, you represented to FDA that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nReference #:\n\nOBPO 621465\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nRobert D. Maguire\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n13825 N. Northsight Blvd., Suite 101\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nAugust 23, 2022\n\nDear Mr. Maguire:\n\nDuring an inspection of your firm, BioLab Sciences, Inc. (hereinafter, “BioLab Sciences”), located at 7662 E. Gray Rd., Suite 107, Scottsdale, AZ 85260, conducted between August 23, 2021, and September 3, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human amniotic fluid, specifically, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), and Stimuleyes™, for allogeneic use, and an epidermal skin tissue product, MyOwnSkin™ and MySkinRestore™, for autologous use (collectively, “your products”).1,2 You have distributed your products to third-party distributors, some under private label, as well as directly to healthcare professionals throughout the United States. Your amniotic fluid products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on your website, www.biolabsciences.com, reflect your products are intended to treat various diseases or conditions. Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act.\n\nMyOwnSkin™ and MySkinRestore™ are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review. 21 CFR 1271.20.\n\nBased on a review of materials described above, BioLab Sciences does not qualify for any exception in 21 CFR 1271.15, and MyOwnSkin™ and MySkinRestore™ fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, MyOwnSkin™ and MySkinRestore™ fail to meet the criterion set forth in 21 CFR 1271.10(a)(1) that they not be more than minimally manipulated as such term is defined for structural tissue in 21 CFR 1271.3(f)(1). Because your processing alters the original relevant characteristics of the skin related to its utility for reconstruction, repair, or replacement, MyOwnSkin™ and MySkinRestore™ are more than minimally manipulated.\n\nMyOwnSkin™ and MySkinRestore™ also fail to meet other criteria set forth in 21 CFR 1271.10(a). An HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” MyOwnSkin™ and MySkinRestore™ are not intended to perform the same basic function or functions of skin in the recipient as in the donor, such as serving as a protective covering. Rather, these products are intended as advanced wound care therapies, including to regenerate skin in various wounds. Such use is not homologous use as defined in 21 CFR 1271.3(c).\n\nAn HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(3) if “the manufacture of the HCT\u002FP does not involve the combination with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT\u002FP.” Based on the processing and product information available for MyOwnSkin™ and MySkinRestore™, skin cells from a patient’s skin are (b)(4) prior to shipment and implantation in the same individual. Therefore, this criterion is also not met.\n\nBecause Biolab Sciences does not qualify for any exception in 21 CFR 1271.15, and because MyOwnSkin™ and MySkinRestore™ do not meet all the criteria in 21 CFR 1271.10(a), these products are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. MyOwnSkin™ and MySkinRestore™ appear to be combination products and would be regulated under the statutory authorities applicable to drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].3\n\nPlease be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your products derived from amniotic fluid, Fluid GF™, Restore GF™, Fluid Flow™, Amnio Retore™, Stimuleyes™, and (b)(4), are also regulated as drugs and biological products under section 351 of the PHS Act and the FD&C Act.\n\nIn order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the inspection, as described below. Additionally, we have received a safety concern about one of your products.\n\nYour CGMP deficiencies, involving over (b)(4) units of products manufactured between March 2019 and the present, include, but are not limited to, the following:\n\n1. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. You failed to validate the aseptic processes used to manufacture over (b)(4) units of Fluid Flow™, Amnio Restore™,(b)(4), Stimuleyes™, Fluid GF™, and Restore GF™ (i.e., by performing media fill simulations) since your manufacturing operations began in March 2019. Based on your product labeling, these products purport to be sterile and are expected to be sterile.\n\nb. Your firm failed to validate the sterilization process for Fluid GF™ and Restore GF™. You have manufactured and distributed over (b)(4) units of these products since June 22, 2021.\n\nc. Your Fluid Flow™ (b)(4) sterilization validation, entitled “(b)(4) Sterilization Validation Report,” RST-1052, dated May 20, 2019, is inadequate. For example:\n\ni. You have had failures during your dose verification audit where it was noted that the established dose to achieve sterility was not adequate and for which you made no changes to your process.\n\nii. You did not assess the impact of the (b)(4) sterilization on the integrity of the amniotic fluid product’s container-closure system to assure that sterility is maintained.\n\nd. The frequency of monitoring conducted in the critical aseptic areas is insufficient to detect problems and demonstrate control. For example:\n\ni. Surface samples for microbiological monitoring are not collected in the Biological Safety Cabinets (BSCs) directly after processing of your amniotic fluid products. Environmental monitoring should be conducted directly after processing, before cleaning is performed, in order to monitor processing conditions and demonstrate control of the critical area during aseptic processing.\n\nii. Personnel monitoring is required only every (b)(4) for personnel who process your amniotic fluid products.\n\ne. In accordance with your cleanroom gowning procedure, personnel performing aseptic processing wear non-sterile personal protective equipment (PPE), such as hair covers, beard covers, and shoe covers, that does not adequately protect against microbiological contamination of your products.\n\nf. During the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products. For example, operators were observed exiting and entering the cleanroom quickly and frequently during manufacturing operations. This practice potentially disturbs the airflow in the cleanroom environment and could introduce contaminants into the cleanroom.\n\ng. Your written environmental monitoring procedure now describes that (b)(4) colony forming units (CFUs) is an acceptable result on environmental monitoring plates intended to detect the presence of microorganisms in the critical processing area. This allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at www.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n2. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, your firm has not established appropriate specifications and test procedures to assure that your amniotic fluid products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to a visual examination.\n\n3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [ 21 CFR 211.67(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your BSCs.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the (b)(4) BSCs used to manufacture your products. For example, your written procedure for cleaning does not include the (b)(4) when (b)(4) is used to clean the BSCs during (b)(4) cleanings.\n\n4. Failure to establish and follow written procedures describing in sufficient detail the methods and materials used for sanitation [21 CFR 211.56(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your cleanrooms.\n\nb. Your firm has not adequately established and followed written procedures for cleaning the cleanrooms used to manufacture your products. For example:\n\ni. In accordance with your cleanroom cleaning procedure, a (b)(4) cleaning of all contact surfaces in the cleanrooms is required at the (b)(4) processing operations. However, a review of your (b)(4) cleaning records revealed that this required cleaning is not always performed, and a justification is not always provided.\n\nii. You failed to ensure sufficient use of (b)(4), a sporicidal agent, in your disinfection program, as required by your cleanroom cleaning procedure. For example, your firm identified Bacillus, species, a spore-forming organism, on your cleanroom floors. You noted that (b)(4) was not used to disinfect the area because the floors were constructed of materials not normally used in cleanrooms.\n\niii. Your written procedure for cleanroom cleaning does not include the (b)(4) when (b)(4) is used during (b)(4) cleanings.\n\niv. The cleaning records do not include dilutions or contact times. During the inspection, no data or rationale for the cleaning agents used or their rotation was provided.\n\n5. Your aseptic processing areas are deficiently designed in that the floors are not smooth, hard surfaces that are easily cleanable in order to prevent contamination [21 CFR 211.42(c)(10)(i)]. For example, your cleanrooms floors have seams and gaps rendering them difficult to clean and disinfect.\n\n6. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed [21 CFR 211.192]. For example, between October 30, 2020, and July 30, 2021, you failed to investigate approximately 90% of your excursions for microbiological monitoring of the cleanroom environment, including two excursions in the critical processing area (i.e., inside your BSCs). While you identified the contaminating organisms, you did not thoroughly investigate the excursions to determine the root cause, product impact, and corrective and preventive actions. Examples of microorganisms identified in your cleanroom include Bacillus species non-anthracis, Fictibacillus species, Bacillus pumilus, Gram Positive Cocci, fungi, and Bacillus megaterium.\n\n7. Failure to ensure that each lot of components, drug product containers, and closures are withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84]. For example:\n\na. Your firm used (b)(4) to manufacture approximately (b)(4) batches of MyOwnSkin™ and MySkinRestore™ between June 27, 2019, and September 24, 2021, even though such components had not been examined and released for use by the quality control unit. These components are labeled for research use only.\n\nb. Your firm used (b)(4), to manufacture MyOwnSkin™ and MySkinRestore™, even though such components had not been examined and released for use by the quality control unit. The labeling of those components advises against their use in “Human or Animal Drugs.”\n\nc. Your firm lacks evidence, such as testing, to demonstrate that these components meet all specifications of identity, strength, quality, and purity.\n\n8. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, your firm has not validated the manufacturing processes for Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™.\n\n9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, your firm has assigned a twelve-month expiration date to your amniotic fluid products and a 24-hour expiration date to your skin products without supporting data from stability testing.\n\nWe have reviewed your written responses, dated September 27, 2021, November 30, 2021, February 14, 2022, March 26, 2022, May 26, 2022, and July 26, 2022, to the inspectional observations on the Form FDA-483, and we have determined that they are inadequate to address our concerns.\n\nWe acknowledge your commitment to voluntarily cease the manufacture and distribution of MyOwnSkin™ and MySkinRestore™ until an IND is in effect for such products.4 You also explain that you currently market amniotic membrane products, Membrane Wrap™ and Membrane Restore™, and amniotic fluid products, Fluid GF™ and Restore GF™, and commit that all other tissue products marketed in the past under additional brand names have been discontinued. Please note that amniotic fluid products are not considered tissue products. We acknowledge that you report having discontinued manufacturing (b)(4), Stimuleyes™, Fluid Flow™, and Amnio Restore™.\n\nYour responses, however, do not adequately address your failure to have an IND in effect for your amniotic fluid products and your lack of an approved BLA to lawfully market those products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nYour response also does not adequately address any inventory of Fluid GF™, Fluid Flow™, Restore GF™, and Amnio Restore™ at your facility. In response to this letter, provide your specific plans for the disposition of all of these products. Please also explain in detail your intention to use your inventory of Fluid Flow™ and Amnio Restore™, currently in quarantine, for “potential research use.”\n\nWe note that you have previously marketed Amnio Breathe™, a nebulizer bundle containing Fluid Flow™. In response to this letter, please also inform FDA whether you are currently marketing this product or intend to in the future.\n\nFinally, we note that in your responses you discuss updates to your procedures in an attempt to comply with CGMP requirements. We have reviewed those updates and listed your CGMP deficiencies above. We are not providing further input on your updates to procedures in this letter.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations and prevent their recurrence. Include any documentation necessary to show that matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Dr. – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Ms. Graf at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\nCc: Robert D. Maguire\n\nPresident and Chief Executive Officer\n\nBioLab Sciences, Inc.\n\n7662 East Gray Road, Suite 107\n\nScottsdale, AZ 85260\n\n_________________________\n\n1 This letter only pertains to Fluid GF™, Restore GF™, Fluid Flow™, Amnio Restore™, (b)(4), Stimuleyes™, MyOwnSkin™, and MySkinRestore™. You also manufacture products derived from amniotic membrane, including Membrane Wrap™, Membrane Restore™, and Vision Sphere™. Please be advised that Membrane Wrap™ does not appear to meet the homologous use only criterion at 21 CFR 1271.10(a)(2). You describe this product as a “human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound and protectant covering.” Use of Membrane Wrap™ as a wound covering would be considered a homologous use. However, you also market this product, for example, to reduce pain and scarring, adhere wounds, heal, and as “anti-bacterial” and for “immune privileged[] and neovascularization.” Such uses are considered nonhomologous uses for amniotic membrane. Membrane Wrap™ must meet all the criteria at 21 CFR 1271.10(a), including the homologous use criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This letter does not otherwise address your amniotic membrane products.\n\n2 Some of your products are the same products marketed under different brand names. For example, you represented to FDA that (b)(4) is the same product as Stimuleyes™. Likewise, MyOwnSkin™ and MySkinRestore™ are the same product marketed under different brand names.\n\n3 As combination products, MyOwnSkin™ and MySkinRestore™ would be appropriately assigned to the Center for Biologics Evaluation and Research (CBER) based on the combination products’ primary mode of action. (b)(4).\n\n4 We note that you had been informed by FDA prior to FDA’s inspection that MyOwnSkin™ appeared to be regulated as a combination product. Nevertheless, you continued to manufacture and distribute this product without premarketing approval until September 24, 2021.","BioLab Sciences, Inc.","biolab-sciences-inc-621465-08232022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiolab-sciences-inc-621465-08232022","2026-10-26T08:08:04.986053+00:00","2022-09-20","621465","Biologics","Robert D. Maguire","2026-08-20T01:33:07.944+00:00","VIA UNITED PARCEL SERVICE","OBPO 621465","2022-08-23",3,{"510k":75,"classification":76,"enforcement":77,"event":78,"event_backfill":79,"pma":80,"warning_letter":81},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]